SCHEDULE 13G/A: BlackRock Amends RxSight Stake to 5.8%

BlackRock, Inc. has filed an amendment to its Schedule 13G, disclosing a 5.8% beneficial ownership stake in RxSight, Inc. as of September 30, 2025.

Summary

• BlackRock, Inc. reported beneficial ownership of 2,393,289 shares of RxSight, Inc. common stock.
• This represents 5.8% of RxSight, Inc.'s total outstanding common stock.
• BlackRock holds sole voting power over 2,356,084 shares and sole dispositive power over 2,393,289 shares.
• The filing is an Amendment No. 2 to a previously filed Schedule 13G, indicating a change in their reported ownership.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of RxSight, Inc.

Sentiment

Score: 5

Explanation: A Schedule 13G filing is generally neutral, indicating a passive ownership stake by a large institutional investor. It doesn't inherently convey positive or negative sentiment about the issuer's performance, but rather reflects an investment position.

Positives

• Increased institutional investor confidence: BlackRock's continued significant stake (5.8%) suggests ongoing confidence in RxSight, Inc. as a long-term investment.
• Stability in ownership: The filing indicates a passive investment strategy, which can contribute to market stability for RxSight's stock.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding RxSight, Inc.'s future performance or BlackRock's investment strategy beyond the certification of passive intent.

Industry Context

The disclosure of a significant stake by a major institutional investor like BlackRock is a routine event in the public markets. It reflects BlackRock's role as a large asset manager holding diversified portfolios, including positions in companies across various sectors, such as healthcare technology where RxSight operates.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's stake, potentially signaling long-term confidence.
• Management: Awareness of a large, passive institutional investor on the shareholder register.

Key Dates

Recommendation

This Schedule 13G filing primarily discloses BlackRock's passive ownership stake in RxSight, Inc. It does not provide new financial performance data, strategic updates, or operational insights that would warrant a 'buy' or 'sell' recommendation. The continued significant, passive stake by a major institutional investor like BlackRock suggests a stable, long-term investment, supporting a 'hold' recommendation for existing investors. New investors would need to conduct further due diligence beyond this ownership disclosure.

Keywords

RxSight, BlackRock, Institutional Ownership, SEC Filing, Schedule 13G, Common Stock, Beneficial Ownership, Investment Management, Healthcare Technology